Michigan Supreme Court permits state‑wide investigation into systemic insulin price inflation and corporate profit practices
Original framing: “STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing” — STAT News
Scientific studies document the clinical necessity of insulin for type 1 diabetes and many type 2 patients, while pharmacoeconomic analyses show that price reductions would not compromise safety or efficacy. Evidence also indicates that biosimilar insulin can achieve comparable outcomes at lower cost when barriers to entry are removed.
The Michigan ruling spotlights a broader, historically rooted system where patent law, market exclusivity, and regulatory capture have turned insulin into a commodity rather than a public good.
By drawing on cross‑cultural examples of price‑reference systems, Indigenous preventive practices, and robust scientific evidence of biosimilar efficacy, a multi‑layered strategy emerges: enforce national price caps, accelerate generic competition, and develop public manufacturing while embedding community‑driven care models. These interventions collectively address the structural drivers of overpricing, restore equity for marginalized patients, and align U.S. insulin policy with global health standards. Actors ranging from Congress and the FDA to community organizations and patient advocacy groups must coordinate to reconfigure the insulin market from profit‑centric to health‑centric.